Pancreatic Ductal Adenocarcinoma Clinical Trials in Washington D.C., District of Columbia

4 studies are recruiting for pancreatic ductal adenocarcinoma in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

   Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surg…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sibley Memorial Hospital ( Site 0310), Washington D.C., District of Columbia

   Locations

   55 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06428409 on ClinicalTrials.gov

2. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

3. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   52 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06586515 on ClinicalTrials.gov

4. Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

   The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadju…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MedStar Georgetown University Hospital, Washington D.C., District of Columbia

   Locations

   93 in total

   Run by

   Panbela Therapeutics, Inc.

   See if you can join NCT05254171 on ClinicalTrials.gov